137756-89-9

Basic information

• Product Name: 4-(2-Hydroxyethyl)phenylboronicacid
• Synonyms: Boronic acid, B-[4-(2-hydroxyethyl)phenyl]-
• CAS NO: 137756-89-9
• Molecular Formula: C₈H₁₁BO₃
• Molecular Weight: 165.9821
• Mol File: 137756-89-9.mol

Chemical Properties

• Boiling Point: 359.891 °C at 760 mmHg
• Flash Point: 171.456 °C
• Appearance: /
• Density: 1.209 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.555
• Storage Temp.: Refrigerated.
• CAS DataBase Reference: 4-(2-Hydroxyethyl)phenylboronicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Hydroxyethyl)phenylboronicacid(137756-89-9)
• EPA Substance Registry System: 4-(2-Hydroxyethyl)phenylboronicacid(137756-89-9)

Safety Data

• Hazardous Substances Data: 137756-89-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry Research:
4-(2-Hydroxyethyl)phenylboronic acid is used as a reagent for [its ability to form stable covalent bonds with different substances], facilitating the synthesis of more complex chemical structures in molecular and synthetic organic chemistry.
Used in Industrial Settings:
4-(2-Hydroxyethyl)phenylboronic acid is used as a versatile intermediate for [its role in the synthesis of complex chemical structures], making it a valuable component in the production of various industrial chemicals.
Used in Therapeutic Agent Development:
4-(2-Hydroxyethyl)phenylboronic acid is used as a potential component in [its utility in the development of therapeutic agents], indicating its potential for use in pharmaceutical applications.

InChI:InChI=1/C8H11BO3/c10-6-5-7-1-3-8(4-2-7)9(11)12/h1-4,10-12H,5-6H2

Upstream product

• 5419-55-6 Triisopropyl borate 
• 4654-39-1 4-bromophenethanol 
• 7732-18-5 water 

Downstream Products

• 415913-36-9 4-{2-[({[(4-Methylphenyl)sulfonyl]amino]carbonyl)oxy]ethyl}phenylboronic acid 
• 202189-78-4 Bilastine 
• 552301-45-8 2-methyl-2-[4'-(2''-hydroxyethyl)phenyl]propanoic acid 
• 137756-90-2 4‐(2‐bromoethyl)phenylboronic acid 

Relevant articles and documents

Tumor diagnosis and treatment integrated boron carrying agent as well as preparation method and application thereof

The invention relates to a tumor diagnosis and treatment integrated boron carrying agent as well as a preparation method and application thereof. A compound of a formula I is provided, the R group is hydrogen or alkyl. Boron atoms attached to a benzene ring may be 10B or natural boron, and at least one fluorine atom in -BF3- is radiolabelled. The present invention relates generally to the field of radiopharmaceuticals and nuclear medicine. The compound provided by the invention can be used for a diagnosis and treatment integrated medicine for tumor diagnosis and BNCT treatment, and a reliable in-vivo distribution result of the medicine is provided through the same chemical structure of the compound.

ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE

Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell impermeable. ENPP1 inhibitor compounds can act extracellularly to block the degradation of cGAMP. Also provided are pharmaceutical compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of an ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject in conjunction with administering an ENPP1 inhibitor to the subject. The radiation therapy can be administered in the subject methods at a dosage and/or frequency effective to reduce radiation damage to the subject, but still instigate an immune response.

SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS

The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

Pyrazole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the formula (I): wherein: R1 represents a hydrogen atom, an alkyl group, etc.; R2 represents a hydrogen atom, a halogen atom, etc.; R3 represents an alkyl group, etc.; R4 re

Imidazole compounds as anti-inflammatory and analgesic agents

This invention provides a compound of the formula (I): wherein: R1 represents a hydrogen atom, an alkyl group, etc.; R2 represents a hydrogen atom, a halogen atom, etc.; R3 represents a hydrogen atom, an alkyl group, etc.;

Use of EP4 receptor ligands in the treatment of IL-6 involved diseases

Methods of treating IL-6 involved diseases with EP4 receptor ligands, including EP4 receptor antagonists. Assays to determine the effect of test compounds on PGE2-induced whole blood cells activation.

EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS

The invention features a method of treating rheumatoid arthritis in a mammal comprising administering an agent that inhibits prostaglandin EP4 receptor (EP4) activity. Also featured is a method of identifying agents that selectively inhibit EP4 activity in vivo.

Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group

Boronic acid adducts of technetium-99m and radioactive rhenium dioxime complexes, each of which include biochemically active groups, are useful as diagnostic and therapeutic agents, respectively.